CardioNet Announces Public Offering of Common Stock

CONSHOHOCKEN, Pa.--(Business Wire)--
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with an initial focus on the diagnosis and
monitoring of cardiac arrhythmias, announced an underwritten public
offering of 4,664,102 shares of common stock by certain of CardioNet's
existing stockholders. The selling stockholders plan to grant to the
underwriters an option to purchase from them an additional 699,615
shares to cover over-allotments, if any. CardioNet will not be selling
any shares of common stock in the offering and will not receive any of
the proceeds from the sale of shares by the selling stockholders.

Citi is the sole book-running manager, Banc of America Securities
LLC and Leerink Swann are the co-lead managers and Cowen and Company
and Thomas Weisel Partners LLC are the co-managers for this offering.
A prospectus relating to these securities may be obtained from the
Prospectus Department of Citi by calling (800) 831-9146, by emailing
batprospectusdept@citigroup.com or by writing to Brooklyn Army
Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220.

A registration statement relating to these securities has been
filed with the Securities and Exchange Commission but has not yet
become effective. These securities may not be sold nor may offers to
buy be accepted prior to the time the registration statement becomes
effective. This communication shall not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of
these securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state.

Statements in this press release that are not strictly historical
are "forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and involve a high degree of
risk and uncertainty. In particular, due to market conditions or
otherwise the selling stockholders may be unable to complete the sale
of common stock under the registration statement, and, even if such
sale is completed, the underwriters for the offering may not exercise
any portion of the over-allotment option.

About CardioNet

CardioNet is the leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant and
timely clinical information regarding an individual's health.
CardioNet's initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias, or heart rhythm disorders, with a
solution that it markets as the CardioNet System. More information can
be found at http://www.cardionet.com.

CardioNet, Inc.
Marty Galvan
Investor Relations
800-908-7103
investorrelations@cardionet.com

Copyright Business Wire 2008